News

Quotient's VP of Pharmaceutical Sciences was featured in the November issue of Pharmaceutical Technology in an article entitled: The Earlier the Better for Formulation Strategies

Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the next three years.

Quotient Sciences, the drug development and manufacturing accelerator, announces that it has completed the rebrand of Arcinova, the Alnwick U.K.-based contract development and manufacturing organization (CDMO). Now called Quotient Sciences - Alnwick, the site has significant expertise in drug substance manufacture, isotope labelling, bioanalysis and drug product development, playing a key role in strengthening Quotient’s services portfolio from candidate selection to commercial manufacturing.

In this interview Stuart McDougall, Head of Bioanalytical Services at Quotient Sciences- Alnwick (Northumberland, UK), discusses the technologies used to generate fast, reliable data for drug development and how recently Arcinova has been acquired by Quotient Sciences. He explains what this new partnership means and how Arcinova/Quotient are preparing to address the needs of the future.

Quotient's VP of Drug Development Sciences, Dr Sarah Stevens, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one or­ganization, in Drug Development & Delivery's Special Feature Report

An interview with Quotient's CEO, Mark Egerton, was featured in the latest 2021 edition of the U.S Pharma and Biopharma Report by Global Business Reports.